121 related articles for article (PubMed ID: 28254656)
1. Gefitinib enhances radiotherapeutic effects of
Xia L; Peng H; Zhiqiang L; Xiaoli Z
Nucl Med Biol; 2017 May; 48():63-68. PubMed ID: 28254656
[TBL] [Abstract][Full Text] [Related]
2. Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.
He P; Li G
Cancer Chemother Pharmacol; 2013 Aug; 72(2):341-8. PubMed ID: 23748900
[TBL] [Abstract][Full Text] [Related]
3. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Sandström K; Haylock AK; Velikyan I; Spiegelberg D; Kareem H; Tolmachev V; Lundqvist H; Nestor M
Cancer Biother Radiopharm; 2011 Oct; 26(5):593-601. PubMed ID: 21834651
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V
J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603
[TBL] [Abstract][Full Text] [Related]
8. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
9. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
[TBL] [Abstract][Full Text] [Related]
12. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
Sundberg AL; Almqvist Y; Tolmachev V; Carlsson J
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):727-9. PubMed ID: 12740721
[TBL] [Abstract][Full Text] [Related]
14. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
17. Fusion of the CH1 domain of IgG1 to epidermal growth factor (EGF) prolongs its retention in the blood but does not increase tumor uptake.
Wang J; Reilly RM; Chen P; Yang S; Bray MR; Gariépy J; Chan C; Sandhu J
Cancer Biother Radiopharm; 2002 Dec; 17(6):665-71. PubMed ID: 12537670
[TBL] [Abstract][Full Text] [Related]
18. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
19. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
